Table 1.
Characteristics of total NCR cohort and patients with and without systemic therapy and below or above 70 years.
| NCR Cohort (n = 1105) |
Patients without Systemic Therapy (n = 658) |
Patients withSystemic Therapy (n = 447) |
p-Value | Patients ≤ 70 Years (n = 759) |
Patients > 70 Years (n = 346) |
p-Value | ||
|---|---|---|---|---|---|---|---|---|
| Age Median (IQI) | 66 (59–72) | 68 (61–74) | 63 (56–70) | < 0.001 | 62 (56–66) | 75 (72–78) | <0.001 | |
| Sex | 0.60 | <0.008 | ||||||
| Male | 690 (62) | 415 (63) | 275 (62) | 454 (60) | 236 (68) | |||
| Female | 415 (38) | 243 (37) | 172 (39) | 305 (40) | 110 (32) | |||
| Side primary tumor | 0.92 | 0.09 | ||||||
| Right | 261 (24) | 154 (23) | 107 (24) | 167 (22) | 94 (27) | |||
| Left | 473 (43) | 285 (43) | 188 (42) | 324 (43) | 149 (43) | |||
| Rectum | 371 (34) | 219 (33) | 152 (34) | 268 (35) | 103 (30) | |||
| Chemoradiotherapy primary tumor | <0.001 | 0.67 | ||||||
| No | 977 (88) | 556 (85) | 421 (94) | 669 (88) | 308 (89) | |||
| Yes | 128 (12) | 102 (15) | 26 (6) | 90 (12) | 38 (11) | |||
| T-status primary tumor | 0.01 | 0.97 | ||||||
| 1 | 27 (3) | 21 (3) | 6 (1) | 19 (3) | 8 (2) | |||
| 2 | 128 (12) | 86 (13) | 42 (10) | 89 (12) | 39 (11) | |||
| 3 | 757 (69) | 455 (69) | 302 (69) | 516 (69) | 241 (70) | |||
| 4 | 185 (17) | 96 (15) | 89 (20) | 129 (17) | 56 (16) | |||
| Missing | 8 (-) | 0 (-) | 8 (-) | 6 (-) | 2 (-) | |||
| Nodal status primary tumor | 0.22 | 0.71 | ||||||
| N0 | 408 (37) | 257 (39) | 151 (34) | 277 (37) | 131 (38) | |||
| N1 | 389 (35) | 224 (34) | 165 (37) | 265 (35) | 124 (36) | |||
| N2 | 306(28) | 177 (27) | 129 (29) | 216 (29) | 90 (26) | |||
| Missing | 2 (-) | 0 (-) | 2 (-) | 1 (-) | 1 (-) | |||
| Stage of disease at diagnosis | < 0.001 | 0.40 | ||||||
| I | 25 (2) | 20 (3) | 5 (1) | 16 (2) | 9 (3) | |||
| II | 102 (9) | 87 (13) | 15 (3) | 65 (9) | 37 (11) | |||
| III | 187 (17) | 162 (25) | 25 (6) | 123 (16) | 64 (19) | |||
| IV | 791 (72) | 389 (59) | 402 (90) | 555 (73) | 236 (68) | |||
| Differentiation grade of CRC | 0.12 | 0.77 | ||||||
| Low | 17 (2) | 7 (1) | 10 (3) | 13 (2) | 4 (1) | |||
| Intermediate | 936 (92) | 577 (93) | 359 (90) | 642 (92) | 294 (92) | |||
| High | 68 (7) | 37 (6) | 31 (8) | 46 (7) | 22 (7) | |||
| Missing | 84 (-) | 37 (-) | 47 (11) | 58 (-) | 26 (-) | |||
| Time to metastases | <0.001 | 0.20 | ||||||
| Synchronous | 823 (75) | 412 (63) | 411 (92) | 574 (76) | 249 (72) | |||
| Metachronous | 282 (25) | 246 (37) | 36 (8) | 185 (24) | 97 (28) | |||
| Number of liver metastases | <0.001 | <0.001 | ||||||
| Median (IQI) | 2 (1–4) | 1 (1–3) | 3 (2–6) | 2 (1–4) | 2 (1–3) | |||
| Missing | 42 | 19 | 23 | 33 | 9 | |||
| CEA level | <0.001 | 0.90 | ||||||
| Median (IQI) | 9 (3.4–36) | 6.3 (3.0–21) | 14 (4.4–74) | 18 (4.0–413) | 17 (4.7–168) | |||
| Unknown | 231 | 180 | 51 | 160 | 71 | |||
| Size largest liver metastasis, mm | 0.002 | 0.30 | ||||||
| Median (IQI) | 25 (16–36) | 23 (16–35) | 27 (16–45) | 25 (15–45) | 26 (18–42) | |||
| Missing | 86 | 45 | 41 | 58 | 28 | |||
| Type of surgery | <0.001 | 0.34 | ||||||
| Wedge/segment resection only | 589 (53) | 416 (63) | 173 (39) | 400 (53) | 189 (55) | |||
| Local ablative therapy only | 95 (9) | 63 (9) | 32 (7) | 59 (8) | 36 (10) | |||
| Wedge/segment and local ablative therapy | 189 (17) | 90 (14) | 99 (22) | 134 (18) | 55 (16) | |||
| Hemihepatectomy with/without ablation/wedge (major resection) | 232 (21) | 89 (14) | 143 (32) | 166 (22) | 66 (19) | |||
| One- or two-stage | <0.001 | 0.84 | ||||||
| 1-stage | 1042 (94) | 643 (98) | 399 (89) | 715 (94) | 327 (95) | |||
| 2-stage | 63 (6) | 15 (2) | 48 (11) | 44 (6) | 19 (6) | |||
| R-status | 0.07 | |||||||
| R0 | 866 (78) | 521 (79) | 345 (77) | 0.37 | ||||
| R1 | 143 (13) | 74 (11) | 69 (15) | 598 (79) | 268 (78) | |||
| Unknown because RFA/MWA | 96 (9) | 63 (10) | 33 (7) | 101 (13) | 42 (12) | |||
| Tumor mutational status | 0.36 | 0.93 | ||||||
| RAS mutation | 362 (51) | 221 (53) | 141 (48) | 247 (50) | 115 (52) | |||
| BRAFV600E mutation | 19 (3) | 10 (2) | 9 (3) | 13 (3) | 6 (3) | |||
| RAS and BRAFV600E wildtype | 335 (47) | 188 (45) | 147 (50) | 233 (47) | 102 (46) | |||
| Missing (RAS and/or BRAF status) | 389 (-) | 239 (-) | 150 (-) | 266 (-) | 123 (-) | |||
Abbreviations: CEA, Carcinoembryonic Antigen; CRC, colorectal cancer; IQI, Interquartile range; MMR, mismatch repair; NCR, Netherlands cancer registry.